2025 Annual Meeting | C140 - Myelopathies: Recognizing and Evaluating Myelopathic Patients for Inflammatory and Vascular Causes

Date Tuesday 04/08/25

Time 07:00 AM - 09:00 AM PDT Add To Calendar

Location San Diego Convention Center | 10

Session Format This program will be presented both in-person and online

On Demand This program will be available in the meeting's On Demand product.

Event Type Seminar

Director(s) Eoin P. Flanagan, MBBCh, FAAN

Topic(s) General Neurology

Learning Objectives Participants should be able to navigate more easily towards the correct diagnosis and avoid diagnostic pitfalls in a patient presenting with myelopathy. Clinical and radiologic pearls will assist the general neurologist in recognizing the cause of myelopathy and ordering the correct investigations to confirm the diagnosis. Attendees will be more aware of specific advances in the field of autoimmune myelopathies (e.g., myelin-oligodendrocyte glycoprotein-IgG associated myelitis) and acute and chronic management of myelopathy (e.g., utility of plasma exchange in a patient with a severe myelitis from aquaporin-4-IgG seropositive neuromyelitis optica spectrum disorder).

CME Available 2.00 CME credits

Core Competencies Patient Care & Procedural Skills, Medical Knowledge, Practice-based Learning and Improvement, Systems-based Practice

Program Level Intermediate

Recommended Audience Fellow, Resident, General Neurologist, Specialist Neurologist, Advanced Practice Provider, Neurohospitalist, Medical Student

Teaching Styles Case-based, Didactic, Audience Participation

Program Materials Program Evaluations

Event Timeline
07:00 AM - 07:05 AM PDT	Introduction	Introduction Eoin P. Flanagan, MBBCh, FAAN
07:05 AM - 07:40 AM PDT	Speaker	Inflammatory Myelopathies: Clinical, Serologic, and Treatment Pearls Maria I. Leite, MD
07:40 AM - 08:15 AM PDT	Speaker	Radiologic Pearls in Vascular and Inflammatory Myelopathies and Their Mimics Eoin P. Flanagan, MBBCh, FAAN
08:15 AM - 08:50 AM PDT	Speaker	Clinical Pearls in Vascular Myelopathy Neeraj Kumar, MD
08:50 AM - 09:00 AM PDT	Q&A	Questions and Answers Eoin P. Flanagan, MBBCh, FAAN, Neeraj Kumar, MD

Faculty Disclosures
Maria I. Leite, MD	The institution of Dr. Leite has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for UCB. The institution of Dr. Leite has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Horizon / Amgen. The institution of Dr. Leite has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB. The institution of Dr. Leite has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Viela/Horizon/Amgen. The institution of Dr. Leite has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for UCB. The institution of Dr. Leite has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Amgen. The institution of Dr. Leite has received research support from Non-Profit Organization - Myaware. The institution of Dr. Leite has received research support from UCB - Ra Pharma. The institution of Dr. Leite has received research support from Non-Profit Organization - Muscular Dystrophy UK.
Neeraj Kumar, MD	Dr. Kumar has nothing to disclose.
Eoin P. Flanagan, MBBCh, FAAN	The institution of Dr. Flanagan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Flanagan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. Flanagan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Horizon Therapeutics. The institution of Dr. Flanagan has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Flanagan has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Pharmacy times. The institution of Dr. Flanagan has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for UCB. The institution of Dr. Flanagan has received research support from Viela Bio. The institution of Dr. Flanagan has received research support from UCB. The institution of Dr. Flanagan has received research support from Roche. Dr. Flanagan has received publishing royalties from a publication relating to health care. Dr. Flanagan has a non-compensated relationship as a Member of medical Advisory Board with The MOG Project that is relevant to AAN interests or activities. Dr. Flanagan has a non-compensated relationship as a Editorial board member with Journal of The Neurologic Sciences that is relevant to AAN interests or activities. Dr. Flanagan has a non-compensated relationship as a Editorial board member with Neuroimmunology Reports that is relevant to AAN interests or activities. Dr. Flanagan has a non-compensated relationship as a Editorial Board Member with Neurology, Neuroimmunology Neuroinflammation (N2) Journal that is relevant to AAN interests or activities.

��ɫ��

��ɫ��